scholarly journals Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel

2020 ◽  
Vol 11 ◽  
pp. 204209862094655
Author(s):  
Zoran Rakusic ◽  
Ana Misir Krpan ◽  
Ivica Sjekavica
Keyword(s):  
Gastric Cancer ◽  
Subcutaneous Tissue ◽  
Growth Factor Receptor ◽  
Multiple Organ ◽  
Fournier’S Gangrene ◽  
Vascular Endothelial ◽  
Clinical Progression ◽  
Perianal Region ◽  
Fournier's Gangrene ◽  
Endothelial Growth Factor

Fournier’s gangrene (FG) is an uncommon form of necrotizing fasciitis, localized on the external genital organs, perianal region, and abdominal wall, accompanied by thrombosis of the feeding arteries, leading to gangrene of the skin and subcutaneous tissue, with manifestations of rapid clinical progression and multiple organ failure. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of vascular endothelial growth factor receptor-2 (VEGFR-2) and prevents the binding of all VEGFR ligands. The literature describes bevacizumab, aflibercept, and regorafenib associated with FG in patients with colorectal cancer. According to our knowledge this is the first report of FG possibly related to ramucirumab in a patient with gastric cancer. If not recognized in time, it can lead to fatal complications.

scholarly journals A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

2016 ◽  
Vol 9 (2) ◽  
pp. 317-320 ◽  
Author(s):  
Michael E. Christiansen ◽  
Timothy Ingall ◽  
Edward C. Lew ◽  
Ramesh K. Ramanathan ◽  
Harshita R. Paripati
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Case Reports ◽  
Growth Factor Receptor ◽  
Metastatic Gastric Cancer ◽  
Vascular Endothelial ◽  
First Case ◽  
Endothelial Growth Factor

Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.

scholarly journals Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells

2010 ◽  
Vol 4 (5) ◽  
pp. 797-802 ◽  
Author(s):  
Yongling Ning ◽  
Keqing Qian ◽  
Chunjian Qi
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Line ◽  
Growth Factor Receptor ◽  
Cancer Cell Line ◽  
Vascular Endothelial ◽  
Ags Cells ◽  
Endothelial Growth Factor

Abstract Background: CD40 is a type α-membrane protein of the tumor necrosis factor receptor super-family, and CD40- induced responses may mediate growth and angiogenesis in carcinoma cells. Objectives: Define the effect of CD40 ligation on AGS gastric cancer cell line and the role of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signals in this process. Methods: We treated AGS cells with 1 μg/mL soluble CD40 ligand (sCD40L) with or without pre-incubation of either anti-VEGF mAb (MAB293) or VEGFR tyrosine kinase inhibitor (SU5416). We determined the growth effects by cell counts or [3H]-thymidine incorporation assay and VEGF levels in cell-free supernatant using enzymelinked immunosorbent assays. Results: The engagement of CD40-induced AGS cells proliferation accompanied by a significant increase autocrine VEGF through PI3K activation (p <0.05), and exogenous VEGF alone had no effect on spontaneous cell growth. SU5416 with a concentration of 8 μM lead to a dramatic decrease in cell survival induced by sCD40L (p <0.05), whereas MAB293 did not have the similar effect (p >0.05). Conclusion: CD40-CD40L interaction promoted AGS cancer cell line proliferation through a VEGFR-dependent signal pathway in the presence of an internal autocrine loop.

scholarly journals Expression and Significances of Contactin-1 in Human Gastric Cancer

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Ji-Wei Yu ◽  
Sheng-Hua Wu ◽  
Rui-qi Lu ◽  
Ju-gang Wu ◽  
Xiao-Chun Ni ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Lymph Node Involvement ◽  
Lymphatic Invasion ◽  
Human Gastric Cancer ◽  
Vascular Endothelial ◽  
Factor C ◽  
Endothelial Growth Factor

Background. This study aimed at determining the relationship between vascular endothelial growth factor-C (VEGF-C), vascular endothelial growth factor receptor-3 (VEGFR-3), and contactin-1 (CNTN-1) expression in gastric cancer (GC).Methods. The expression level of CNTN-1 mRNA and CNTN-1 protein of 33 cases was determined using RT-PCR and Western Blot. And 105 cases were immunohistochemically examined for VEGF-C, VEGFR-3, and CNTN-1 expressions. Assessment of lymphatic vessel density (LVD) was also performed by D2-40 immunostaining. Then we analyzed the relationships between VEGF-C, VEGFR-3, and CNTN-1, as well as their correlations with clinicopathologic features, LVD, and survival time.Results. The positivity rate of VEGF-C, VEGFR-3, and CNTN-1 in primary tumor was 56.19%, 64.76%, and 58.09%. The expression of CNTN-1 significantly correlated with VEGF-C (P<0.001) and VEGFR-3 (P<0.001). All of them were closely related to TNM stage, lymphatic invasion, and lymph node involvement (P<0.05). LVD was significantly correlated with VEGF-C (P=0.001), VEGFR-3 (P=0.011), and CNTN-1 expression (P<0.001). VEGF-C, VEGFR-3, and CNTN-1 expression significantly associated with poorer prognosis (P<0.001,P=0.034,P=0.012, resp.).Conclusion. CNTN-1 associated with VEGF-C and VEGFR-3 expression in GC. All of them correlated with lymphatic metastasis, which might play an important role in the lymphatic invasion via lymphangiogenesis pathway in GC.

Sign in / Sign up

Export Citation Format

Share Document